Efficacy of simultaneous vaccination with Enterisol® Ileitis and Ingelvac® CircoFLEXTM in a Swiss breeding farm by Weibel, H et al.
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2012
Efficacy of simultaneous vaccination with Enterisol® Ileitis and Ingelvac®
CircoFLEXTM in a Swiss breeding farm
Weibel, H; Sydler, T; Brugnera, E; Voets, H; Grosse Liesner, B; Sidler, X
Abstract: This study explores administration of two piglet vaccines as compared to the mono- and
adjuvant-application. A vaccine against the Porcine Circovirus Type 2 (PCV2) cap protein subunit
and a vaccine with attenuated live culture against Lawsonia (L.) intracellularis were applied to piglets
aged 23.5 days on average. 1’405 animals were divided randomly into four groups. One piglet group
was immunized with both vaccines while two other groups were immunized with a combination of one
vaccine and adjuvants of alternate vaccination protocol and vice versa. These piglet groups were also
compared to a control group supplemented with both adjuvants only. During fattening, pigs, which were
simultaneously immunized with Enterisol(®) Ileitis and Ingelvac(®) CircoFLEX(TM) vaccine, gained
significantly more weight (792 g/day) when compared to piglet groups mono-vaccinated with Ingelvac®
CircoFLEXTM (772 g/day) or either with Enterisol® Ileitis (774 g/day). Moreover, immunized piglet
groups showed significantly higher daily weight gain when compared to adjuvants only inoculated control
group (751 g/day). Additionally, during fattening the control group displayed higher mortality (6,3 %)
than the three vaccinated groups (Ingelvac(®) CircoFLEX(TM) 2,5 %, Enterisol(®) Ileitis 2,3 % and the
combination of both vaccines 1,1 %). These data imply that simultaneous immunization with PCV2-
and L. intracellularis specific vaccines positively benefit piglet growth observed by an additive effect on
growth parameters in farms harboring both pathogens. Return of investment was calculated of 2.10 on
the additional Enterisol(®) Ileitis vaccination.
DOI: 10.1024/0036-7281/a000381
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: http://doi.org/10.5167/uzh-73958
Accepted Version
Originally published at:
Weibel, H; Sydler, T; Brugnera, E; Voets, H; Grosse Liesner, B; Sidler, X (2012). Efficacy of simultaneous
vaccination with Enterisol® Ileitis and Ingelvac® CircoFLEXTM in a Swiss breeding farm. Schweizer
Archiv für Tierheilkunde, 154(10):445-450. DOI: 10.1024/0036-7281/a000381
 1 
 
Efficacy of simultaneous vaccination with Enterisol® Ileitis and Ingelvac® 1 
CircoFLEXTM in a Swiss breeding farm   2 
 3 
H. Weibel1, T. Sydler2, E. Brugnera1, H. Voets3, B. Grosse Liesner3, X. Sidler1 4 
 5 
1Department for Farm Animals, Division Swine Medicine, University of Zurich 6 
2Institute of Veterinary Pathology, University of Zurich, Switzerland, 3Boehringer 7 
Animal Health GmbH, Ingelheim, Germany 8 
 9 
Summary 10 
 11 
This study explores administration of two piglet vaccines as compared to the mono- 12 
and adjuvant-application. A vaccine against the Porcine Circovirus Type 2 (PCV2) 13 
cap protein subunit and a vaccine with attenuated live culture against Lawsonia (L.) 14 
intracellularis were applied to piglets aged 23.5 days on average. 1`405 animals were 15 
divided randomly into four groups. One piglet group was immunized with both 16 
vaccines while two other groups were immunized with a combination of one vaccine 17 
and adjuvant’s of alternate vaccination protocol and vice versa. These piglet groups 18 
were also compared to a control group supplemented with both adjuvants only. 19 
During fattening, pigs, which were simultaneously immunized with Enterisol® Ileitis 20 
and Ingelvac® CircoFLEXTM vaccine, gained significantly more weight (792 g/day) 21 
when compared to piglet groups mono-vaccinated with Ingelvac® CircoFLEXTM (772 22 
g/day) or either with Enterisol® Ileitis (774 g/day). Moreover, immunized piglet groups 23 
showed significantly higher daily weight gain when compared to adjuvants only 24 
inoculated control group (751 g/day). Additionally, during fattening the control group 25 
displayed higher mortality (6.3%) than the three vaccinated groups (Ingelvac® 26 
CircoFLEXTM 2.5%, Enterisol® Ileitis 2.3% and the combination of both vaccines 27 
1.1%). These data imply that simultaneous immunization with PCV2- and L. 28 
intracellularis specific vaccines positively benefit piglet growth observed by an 29 
additive effect on growth parameters in farms harboring both pathogens. Return of 30 
investment was calculated of 2.10 on the additional Enterisol® Ileitis vaccination. 31 
 32 
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Wirkung einer gleichzeitigen Verabreichung von Enterisol® Ileitis und Ingelvac® 35 
CircoFLEXTM in einem schweizerischen Zuchtbetrieb  36 
 37 
Zusammenfassung 38 
 39 
Die vorliegende Untersuchung verglich die zeitgleiche Applikation zweier Vakzinen 40 
an Ferkel vergleichend zu den Monoapplikationen bzw. zur Adjuvansapplikation der 41 
Kontrolltiere. Verwendet wurde an durchschnittlich 23.5 Tagen alten Ferkeln eine 42 
Subunit-Vakzine gegen das Cap Protein des porzinen Circovirus Typ 2 (Ingelvac® 43 
CircoFLEXTM) und eine attenuierte Lebendvakzine gegen Lawsonia (L.) intracellularis 44 
(Enterisol® Ileitis). 1405 Ferkel wurden randomisiert in 4 Gruppen eingeteilt. Eine 45 
Gruppe wurde mit beiden Vakzinen immunisiert, 2 weitere Gruppen erhielten nur je 46 
eine der Vakzinen bei gleichzeitiger Applikation des Adjuvans des anderen 47 
Impfstoffes. Die Kontrollgruppe wurde nicht vakziniert, erhielt aber beide Adjuvantien. 48 
Die Tiere, die beide Vakzinen erhielten, zeigten in der Mast eine signifikant höhere 49 
Masttageszunahme (792 g/Tag) verglichen mit den Monoanwendungen (Ingelvac® 50 
CircoFLEXTM: 772 g/tag bzw. Enterisol® Ileitis: 774 g/Tag). Die Ferkel mit den 51 
Monoanwendungen wiesen wiederum in der Mast signifikant erhöhte 52 
Masttageszunahmen auf im Vergleich zu der nicht geimpften und nur mit Adjuvans 53 
behandelten Kontrolltieren. Auch die Mortalität in der Mast reduzierte sich durch die 54 
Impfungen im Vergleich zu den Kontrollen (Mortalitätsraten: Kontrolltiere: 6.3%; 55 
Ingelvac® CircoFLEXTM: 2.5%; Enterisol® Ileitis: 2.3%; Kombination beider Vakzinen: 56 
1.1%). Die Daten zeigen, dass die gleichzeitige Immunisierung gegen PCV2 und L. 57 
intracellularis in einem Betrieb mit Infektionen mit beiden Erregern einen additiven 58 
Effekt auf die Wachstumsperfomance in der Mast bewirkt. Der Return on Investment 59 
für die zusätzliche Impfung mit Enterisol® Ileitis wurde mit 2.10 berechnet. 60 
 61 
Schlüsselwörter: PCV2, L. intracellularis, Ferkelimpfung, Leistungsparamter 62 
 63 
Introduction 64 
 65 
Porcine proliferative enteropathy (PPE) caused by Lawsonia (L.) intracellularis, and 66 
porcine circovirus type 2 (PCV2) associated disease, (PCVD) (Segales et al., 2005) 67 
are an economical drag in pig production worldwide. 68 
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L. intracellularis is an obligate intracellular, gram-negative acid-resistant, bacillary 69 
bacterium (McOrist et al., 1995). PPE can be manifested acute, chronic or 70 
subclinical. In Switzerland, the chronic form of PPE is mainly observed in pigs 71 
between 6 to 20 weeks of age (McOrist and Gebhart, 1999). Clinically conspicuous 72 
signs are reduced growth, decreased feed conversion, weight inhomogeneity among 73 
animals of the same age and diarrhea. In Switzerland, a seroprevalence to L. 74 
intracellularis of 67% lies above the European average (Caspari et al., 2005). PCVD 75 
includes among other diseases postweaning multisystemic wasting syndrome 76 
(PMWS) and porcine dermatitis and nephropathy syndrome (PDNS) (Segales et al., 77 
2005). Symptoms of PMWS are wasting, profuse therapy-resistant diarrhea, 78 
dyspnea, enlarged lymph nodes, anemia and occasional icterus, as well as increase 79 
of gastric ulcers (Harding and Clark, 1997b; Allan and Ellis, 2000a). However, PMWS 80 
and chronic PPE are symptomatically hardly distinguishable. PDNS diseased animals 81 
are different since, most show skin lesions of round to irregular, red to purple 82 
macules and papules, and glomerulonephritis. 83 
The live attenuated vaccine Enterisol® Ileitis (Boehringer Ingelheim Vetmedica 84 
GmbH, Germany) protective to PPE was approved 2005 in Switzerland. An effectivity 85 
study established vaccine potency and economic viability under Swiss breeding 86 
conditions (Caspari et al., 2009). Ingelvac® CircoFLEXTM (Boehringer Ingelheim 87 
Vetmedica GmbH, Germany) was approved for suckling piglets 2008 to PCVD 88 
prophylaxis in Switzerland., Numerous studies were conducted on the vaccine’s 89 
viability globally: vaccinated animals showed better performance parameters and 90 
lower mortality rates (Fachinger et al., 2008; Kixmöller et al., 2008; Desrosier et al., 91 
2009).  92 
In pig production, Switzerland shows distinctive characteristics that deviate from 93 
other European countries. The farms are small with an average of 41.7 dams per 94 
breeding farm (SUISAG, 2009), and frequently by-products of the food industry will 95 
be mainly used for fattening pigs. Moreover, Switzerland is free of porcine 96 
reproductive and respiratory syndrome (PRRS), Aujeszky disease (Schwermer and 97 
Sievi, 2010), the classical and African swine fever (BVET, 2009). From 1996 to 2004, 98 
in Switzerland a coordinated effort was undertaken to eradicate and control largely all 99 
Mycoplasma (M.) hyopneumoniae and Actinobacillus pleuropneumoniae (APP) 100 
(Staerk et al., 2007) caused diseases. Since, both diseases became extremly rare.  101 
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Although Enterisol® Ileitis was efficient for mono-infected animals, in some Swiss 102 
farms with L. intracellularis infection the vaccine did not lead to substantial 103 
improvement. An explanation was to speculate about the presence of mixed infection 104 
with PCV2 as additionally PMWS is clinically hardly distinguishable from chronic 105 
PPE.  106 
Therefore, we tested simultaneous administration of both vaccines Enterisol® Ileitis 107 
and Ingelvac® CircoFLEXTM in a farm with separate breeding and fattening barns with 108 
PCV2 and L. intracellularis infections. We compared double immunized pigs 109 
performance parameters to control groups that were immunized with one vaccine and 110 
alternate adjuvant’ and vice versa, and a group with the two adjuvants only. The data 111 
indicate that the piglet group with both immunization protocols showed an additive 112 
benefit on weight performance. 113 
 114 
Material and methods 115 
 116 
Choice of farm 117 
The study was conducted from May 2008 until May 2009 in a farm of sealed 118 
production systems with separate breeding and fattening barns. At the breeding farm 119 
with 58 farrowing pens and approximately 700 weaning places there was a turnover 120 
of 200 sows on yearly average. On average of 8 sows were farrowing each week. 121 
The piglets were weaned at 4 to 5 weeks of age and stayed 10 to 12 weeks at the 122 
farm. 123 
The fattening farm contained 800 places with fully- or partly slatted floors for 7 to 14 124 
pigs. Necropsy confirmed PCVD presence in the breeding as well as in the fattening 125 
farm according to internationally recognized criteria (Sorden, 2000; www.pcvd.org). 126 
The infection with L. intracellularis was detected bioScreen Ileitis antibody ELISA. 127 
Seroprevalence increased from 1.7% in week 7 to 77.6% in week 12. The farm was 128 
subjected to herd screening for PRRS viruses, salmonella, M. hyopneumoniae, 129 
Brachyspira (B.) hyodysenteriae and B. psilosicoli before begin of study and all 130 
probed animals were found negative for these pathogens. 131 
 132 
Experimental composition 133 
The study comprises a total of 1`565 animals in 4 test groups: 134 
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• Control group: Adjuvant for Enterisol® Ileitis and adjuvant for Ingelvac® 135 
CircoFLEXTM 136 
• Group CF: Ingelvac® CircoFLEXTM and adjuvant for Enterisol® Ileitis 137 
• Group EI: Enterisol® Ileitis and adjuvant for Ingelvac® CircoFLEXTM 138 
• Groups EI+CF: Enterisol® Ileitis and Ingelvac® CircoFLEXTM 139 
 140 
Ingelvac® CircoFLEXTM   vaccine active component is the baculovirus expressed cap 141 
protein of PCV2. It is approved for animals aged two weeks and above. Immunization 142 
protection within 2 weeks is gained by active immunization and lasts a minimum of 17 143 
weeks. According to the manufacturer’s information the Enterisol® Ileitis vaccine 144 
consists of live attenuated L. intracellularis (MS B3903). The freeze-dried bacteria are 145 
diluted with water and administered orally to the suckling pigs aged 3 weeks and 146 
above. This active immunization results in protection 3 weeks after vaccination. 147 
Suckling piglets of two subsequent weeks were treated equally. The 4 groups were 148 
picked randomly within a time frame of 8 weeks. This was done thrice while test 149 
groups were always arranged randomly. All piglets pertaining to one group were 150 
taken off at the same time and not mixed with the animals of another group. The 151 
owner was only informed of group affiliation at the end of the study.  152 
 153 
Vaccination protocol, animal identification, measurement of performance parameters 154 
and laboratory monitoring 155 
Vaccination with Enterisol® Ileitis and Ingelvac® CircoFLEXTM or their respective 156 
adjuvants took place between day 19 and day 30. During vaccination procedures all 157 
animals were weighed, gender and heritage were noted and an electronic ISO- 158 
(International Organization for Standardization) earmark was applied. A second 159 
weighing took place in week 12 (end of weaning). Slaughter age and weight were 160 
noted directly at the slaughterhouse. Live weight at time of slaughtering was 161 
calculated based on the carcass weight divided by 79.5%. 162 
One suckling pig per litter or at least 10 suckling pigs were randomly chosen and 163 
additionally marked. Blood samples were taken from these animals during week 3, 7, 164 
12, 15 and 18 (EDTA-blood). At the bioScreen laboratory in Munster (Germany) the 165 
sera were tested for the presence of L. intracellularis antibodies via bioScreen Ileitis 166 
antibody ELISA. PCV2 virus was identified in pig blood by real-time PCR with aid of 167 
SYBR Green (Roche Diagnostics AG, Rotkreuz, Switzerland) at the Institute of 168 
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Veterinary Pathology, University of Zurich. DNA extraction was done with the MagNA 169 
Pure LC Total Nucleic Acid Isolation Kit (Roche Diagnostics AG, Rotkreuz, 170 
Switzerland). 171 
75% of the animals that died and 100% of animals euthanized due to their poor 172 
general condition were examined at the Institute of Veterinary Pathology, University 173 
Zurich by necropsy and histology. Mesenteric lymph node, ileum, tonsils and spleen 174 
were investigated and immunohistochemically tested for the presence of PCV2 using 175 
the F217 monoclonal antibody (McNeilly et al. 2001, Wiederkehr et al. 2009). L. 176 
intracellularis infection was tested by macroscopical and histological evaluation of the 177 
ileum mucosa and using histological Warthin-Starry silverstaining (W+S) to dye 178 
intracellular rods in the enterocytes of the ileal crypt cells. W+S was not applied in 179 
cases of advanced autolysis or unspectacular histology of the intestinal crypts. 180 
 181 
Animals excluded from study 182 
Sick animals or animals weighing less than four kilograms at weaning as well as 183 
piglets destined for breeding were vaccinated, however they were not included in the 184 
study. 66 piglets were not included due to a significantly higher average weight at 185 
time of vaccination. Other 63 piglets were also excluded from the study due to a 186 
massive outbreak of E. coli-diarrhoea that required peroral antibiotic treatment. 187 
Individual animals were excluded if they were not weaned with the other animals in 188 
their group, or they were moved to another administration group (n=31) later on. 189 
 190 
Calculation of return on investment (ROI) and statistics 191 
The economic impact of the fattening farm (week 12 to slaughtering) is expressed by 192 
the return on investment (ROI) per year, i.e. the extra profit of X Swiss francs 193 
generated per 1 Swiss franc invested. A price for slaughtered pigs of 3.60 CHF/kg 194 
(2.40 €/kg), a price of 4.40 CHF/kg (2.93 €/kg) per piglet at 30 kg and a price of 6.00 195 
CHF (4.00 €) for both vaccines in total were taken as a basis for the calculation. 196 
Daily weight gains were analyzed with an ANOVA without co-variables. To compare 197 
mortality rates a Chi-Square-Test was applied. SAS (Statistical Analysis System; 198 
Version 8.2, Cary, USA) software was used for statistical analysis. 199 
 200 
Results 201 
Group allocation 202 
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Parameters to pigs’ random distribution at the beginning of the study are illustrated in 203 
table 1. No significant differences among the groups with regard to starting weight 204 
and gender division was observed. 205 
 206 
Laboratory analysis 207 
PCV2 DNA template concentrations and ELISA results of L. intracellularis antibodies 208 
from randomly selected pigs are shown in table 2. The virus titer of the groups 209 
vaccinated with Ingelvac® CircoFLEXTM remained on the base level and was one to 210 
two common logarithms lower after week 7 as compared to the unvaccinated group. 211 
There were no significant differences in L. intracellularis antibody values of the 212 
groups with or without the Enterisol® Ileitis vaccination. A strong increase in 213 
seroprevalence of the L. intracellularis antibodies between the 7th and 15th week was 214 
observed. 215 
 216 
Mortality rates and necropsy results 217 
During the study group sizes reduced from 1`405 animals in the beginning to 1`359 218 
pigs in week 12 due to death (n=29) and untimely selling of animals (n=17). A further 219 
group size reduction occurred before slaughter (to n=1`246) due to deaths (n=40) 220 
and animals sold untimely (n=17). For 20 additional pigs no data could be raised due 221 
to loss of earmark; 36 animals had to be moved to another fattening stable due to 222 
space shortage after week 18. 223 
Table 3 illustrates mortality rates during weaning and fattening period. All vaccinated 224 
group showed a significantly decreased mortality rate with the double immunized 225 
group significantly lowest mortality.  226 
In total, 55 animals were examined at the Institute of Veterinary Pathology, University 227 
of Zurich. 28 pigs died of PCVD (Figure 1). Whereby, 22 pigs died of PMWS, 1 of 228 
PDNS and 5 of a mixed form. Intracellular rods in enterocytes of the ileo-mucosa 229 
were found in 4 animals by W+S staining. These animals also showed histological 230 
lesions typical for L. intracellularis infection. Three of the four W+S positive animals 231 
showed also signs of PMWS, namely, one animal from the control group and two 232 
from the group EI. The fourth animal exhibits intracellular rods pertained to 233 
administration group EI+CF and died of a right ventricle insufficiency. Of the other 27 234 
animals examined, 9 died of intestinal torsion, 5 died due to diarrhea at the age 235 
between 37 and 56 days. In one of these pigs E. coli (O141:K85) was confirmed. For 236 
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the other 13 animals various diseases independently of PCV2 and L. intracellularis 237 
infections were diagnosed. 238 
 239 
Daily weight gain 240 
Table 4 illustrates daily weight gain during fattening period. Average daily weight gain 241 
(ADWG) during fattening was significantly higher in the immunized groups compared 242 
to control group. The combined vaccinated group EI+CF showed significantly higher 243 
ADWG (+ 41 g/d) than single immunized group EI (+ 23 g/d) or CF (+ 21 g/d). 244 
However, ADWG was not improved after vaccination in the weaning period. 245 
Interestingly, slight reduction of ADWG was seen even in some vaccinated groups, 246 
which was more than compensated during fattening. Hence, the economic benefit of 247 
Enterisol® Ileitis with lower mortality rate (- 1.4 %) and augmented ADWG (+ 20 g/d) 248 
on the level of an already PCV2 immunized pig population in the fattening period is 249 
illustrated by the ROI of 2.10. 250 
 251 
Discussion 252 
 253 
During fattening period it was obvious that the simultaneous administration of 254 
Enterisol® Ileitis and Ingelvac® CircoFLEXTM (group EI+CF) led to significantly higher 255 
average daily weight gain (ADWG) and reduced mortality rates as compared to the 256 
control and to mono vaccinated groups (groups CF and EI). Ingelvac® CircoFLEXTM 257 
vaccinated group showed significantly reduced mortality, increased ADWG and none 258 
died by PCVD. Also, Enterisol® Ileitis vaccinated group reduced significantly mortality 259 
and increased ADWG. 260 
Side effects with the simultaneous application of Enterisol® Ileitis and Ingelvac® 261 
CircoFLEXTM were not systematically checked; however, the owner as well as the 262 
respective veterinarian did not observe any negative reactions including sudden 263 
death, systemic allergic reactions and local swelling in all vaccinated groups (more 264 
than 1000 pigs). Furthermore, the combined vaccination supported the best 265 
performance.  266 
The impact of the Ingelvac® CircoFLEXTM vaccination was also seen in the PCV2 267 
genome content of the blood. The virus titer of the groups vaccinated with Ingelvac® 268 
CircoFLEXTM was one to two common logarithms lower after week 7 as compared to 269 
the unvaccinated group. This led most probably to a decrease in PCV2 infection 270 
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pressure on the stock and one may even assume that unvaccinated control animals 271 
profited from the PCV2 infection pressure decrease. Similar PCV2 genome values 272 
were described in earlier studies (Cline et al., 2008; Fachinger et al., 2008).  273 
The increase in PCV2 genome concentrations between week 7 to week 12 in 274 
animals not vaccinated with Ingelvac® CircoFLEXTM, and the seroconversion against 275 
L. intracellularis after week 7 led to the conclusion that vaccination during week 3 276 
was early enough for both vaccines. Considering the allocation of deaths during 277 
weaning and fattening time, the increase in PCV2 genome content between week 7 278 
to week 12 PCV2 specific immunization prevented PCVD mortality in the fattening 279 
period. 280 
Groups that received an immunization (CF group and EI group) showed significantly 281 
higher ADWG during fattening period compared to control group (Enterisol® Ileitis 282 
+22g/day; Ingelvac® CircoFLEXTM +21g/day). These results are in agreement with 283 
various other studies ( Fachinger et al., 2008; Kixmöller et al., 2008; Caspari et al., 284 
2009). Nevertheless, the combination of the immunization (group EI+CF) attributed to 285 
the best growth on individual pig with an average of +41g/day on top of the control 286 
group’ growth during the fattening period. 287 
Seroprevalence of L. intracellularis in Swiss farms is high at 67% and this fact is 288 
interpreted that L. intracellularis infection might often appear only in a subclinical 289 
form. In the investigated farm only few animals were diagnosed clinically suspicious 290 
for PPE, probably most animals were subclinically infected with L. intracellularis. This 291 
assumption is further supported by the considerable less ADWG during fattening 292 
period of the control group and EI or CF group compared with double vaccinated 293 
group (EI+CF group). Thus, this combined vaccination strategy against PCV2 and L. 294 
intracellularis will reduce antibiotic application and more importantly will significantly 295 
increase growth and concomitantly decrease pigs mortality. In spite of increased 296 
production costs the economic benefit of the combined vaccination outweighs 297 
reflected by ROI of 2.10 by the additional Enterisol® Ileitis. 298 
 299 
 300 
 301 
 302 
 303 
 304 
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Table 1: Administration groups with number of animals (n), starting weight, -age and 305 
gender division. 306 
 307 
 308 
 
Parameters 
 
Control 
group 
 
CF 
 
EI 
 
EI + CF 
 
Total 
 
Number of animals (n) 
 
327 
 
376 
 
318 
 
384 
 
1`405 
Weight at vaccination (kg) 6.54 6.60 6.59 6.78 6.63 
Age at start (day p.p.) 23.4 23.1 23.1 24.2 23.5 
Female (%) 42.2 39.6 41.5 39.3 40.6 
Male, castrated (%) 57.8 60.4 58.5 60.7 59.4 
 309 
 310 
 311 
 312 
 313 
 314 
 315 
 316 
 317 
 318 
 319 
 320 
 321 
 322 
 323 
 324 
 325 
 326 
 327 
 328 
 329 
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Table 3: Mortality rates during weaning and fattening period. 330 
 331 
 
Time  
 
Parameters 
 
Control  
 
   CF 
 
   EI 
 
EI+CF 
 
Total 
 
Total 
 
Number of animals (n) 
 
327 
 
376 
 
318 
 
384 
 
1`405 
  
Mortality rate (%) 
 
8.3a 
 
4.0b 
 
5.3ab 
 
2.6b 
 
4.9 
 
Weaning 
 
Number of animals (n) 
 
327 
 
376 
 
318 
 
384 
 
1`405 
  
Mortality rate (%) 
 
2.1 
 
1.6 
 
3.1 
 
1.6 
 
2.1 
 
Fattening 
 
Number of animals (n) 
 
318 
 
367 
 
306 
 
368 
 
1`359 
  
Mortality rate (%) 
 
6.3a 
 
2.5b 
 
2.3b 
 
1.1b 
 
2.9 
 332 
Indices a/b mark deviations between the administration groups with a significant level of p ≤ 0.05. 333 
 334 
 335 
 336 
 337 
 338 
 339 
 340 
 341 
 342 
 343 
 344 
 345 
 346 
 347 
 348 
 349 
 350 
 351 
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Table 4: Daily weight gains during fattening period (week 12 to slaughtering). 352 
 353 
 
Parameters 
 
Control group 
 
CircoFlex 
 
Enterisol 
 
EI+CF 
 
Number of animals (n) 
 
283 
 
312 
 
292 
 
359 
 
Daily weight gains  
during fattening (g/day) 
 
751a 
 
772b 
 
774b 
 
792c 
 354 
Indices a/b/c mark deviations between the administration groups with a significance level of p ≤ 0.05. 355 
356 
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Table 2: L. intracellularis specific antibodies in serum and PCV2 DNA template 357 
concentrations (as log 10 of PCV2 DNA template content per ml) in pig blood, 358 
separated according to age. 359 
 360 
 Lawsonia antibodies (%) ) PCV2 genom  es 
week positive negative doubtful with 
CircoFLEXTM 
without 
CircoFLEXTM 
3 4.4 91.6 4.0 4.2 4.1 
7 0.9 96.3 2.7 4.4 4.5 
12 76.6 14.0 9.3 4.1 5.8 
15 90.9 4.3 4.8 4.3 6.1 
18 84.6 6.5 9.0 4.1 6.0 
 361 
 362 
 363 
 364 
 365 
 366 
 367 
 368 
 369 
 370 
 371 
 372 
 373 
 374 
 375 
 376 
 377 
 378 
 379 
 380 
 381 
 382 
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Figure 1: Deaths due to a PCV2 infection. 383 
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